Subunit vaccine

Akston Biosciences Announces Commercial Supply Agreement of Seppic’s Adjuvant to Formulate Akston Shelf-Stable COVID-19 Vaccine at Global Scale

Retrieved on: 
Wednesday, July 21, 2021
Research, Infectious diseases, Chemicals, Plastics, Clinical trials, Manufacturing, Biotechnology, Pharmaceutical, Health, Science, Other Science, Vaccination, Vaccine, Virology, Subunit vaccine, University Medical Center Groningen, Subunit, Aks, Medicine, Health care, Health

The two companies began collaborating for the development of AKS-452 in the summer of 2020.

Key Points: 
  • The two companies began collaborating for the development of AKS-452 in the summer of 2020.
  • AKS-452 is a protein subunit vaccine that is in Phase II testing at the University Medical Center Groningen (UMCG), one of the largest hospitals in the Netherlands.
  • We are excited to work together to combine the great potential of Akstons AKS-452 with Seppics deep experience in vaccine adjuvants.
  • We are confident about the potential for AKS-452 to transform the global COVID-19 landscape for those most at risk, said Todd Zion, Ph.D., President & CEO of Akston Biosciences.

Valneva and Pfizer Complete Recruitment for Phase 2 Trial of Lyme Disease Vaccine Candidate

Retrieved on: 
Monday, July 19, 2021
Medical specialties, Lyme disease, Medicine, Microbiology, Borrelia, Valneva SE, Vaccine, Willy Burgdorfer, Subunit vaccine, Lyme disease microbiology

Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, This recruitment completion represents another important milestone in the development of VLA15.

Key Points: 
  • Juan Carlos Jaramillo M.D., Chief Medical Officer of Valneva, said, This recruitment completion represents another important milestone in the development of VLA15.
  • If successful, this trial could enable the inclusion of a pediatric population in the Phase 3 trial.
  • VLA15 is the only active Lyme disease vaccine candidate in clinical development today, and covers six serotypes that are prevalent in North America and Europe.
  • This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi, the bacteria that cause Lyme disease.

New Preclinical Data Demonstrate Potential of Codiak’s Engineered Exosomes as Novel, Targeted Approaches in Multiple Disease Areas

Retrieved on: 
Tuesday, May 11, 2021
Medical specialties, Branches of biology, Medicine, Immune system, Immunology, Vaccines, Exosome, Vesicles, Vaccine, Antigen, Polyclonal antibodies, Subunit vaccine

\xe2\x80\x9cBy using exosomes to enhance the therapeutic index, we can pursue previously undruggable pathways and targets in multiple disease areas.

Key Points: 
  • \xe2\x80\x9cBy using exosomes to enhance the therapeutic index, we can pursue previously undruggable pathways and targets in multiple disease areas.
  • The data presented at ASGCT show that this platform enables antigen-specific immune responses that can be modulated through antigen orientation and adjuvant loading.
  • Further, multiple exoVACC vaccine constructs induced superior systemic and tissue-resident immune responses via various routes of administration compared to conventional vaccine formulations in animal models of both infectious disease and oncology.
  • Specific to SARS-CoV-2, an exosome loaded with a receptor-binding domain on the surface generated robust neutralizing antibodies against the virus without requiring adjuvants.

Global Vaccine Adjuvants Market to 2025 - Increasing Use of Recombinant Subunit and Synthetic Vaccines - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 10, 2021
Health, Pharmaceutical, Medical specialties, Vaccines, Medicine, Health care, Virology, Vaccination, Vaccine, Adjuvant, Immunologic adjuvant, Subunit vaccine, COVID-19 vaccine, DNA vaccine

The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing use of recombinant subunit and synthetic vaccines.

Key Points: 
  • The propelling factors for the growth of the vaccine adjuvants market include the unmet needs for vaccines against certain diseases, expanding government recommendations for immunizations, technological innovations, and increasing use of recombinant subunit and synthetic vaccines.
  • The adjuvant market is gaining a boost from the increasing use of recombinant subunit vaccines.
  • Over the coming years, more developments are expected to take place, increasing the need for adjuvants.
  • Thus, the negative impacts of toxicity of adjuvants on vaccine manufacturing cost and safety profiles of vaccines are hindering the growth of the market.

Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan

Retrieved on: 
Monday, January 25, 2021
Vaccines, Adjuvants, Subunit vaccine, Health sciences, Clinical trials, Health, H5N1 clinical trials, Medical research

MVC-COV1901is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.

Key Points: 
  • MVC-COV1901is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax.
  • MVC's Phase 2 clinical trial is a randomized, double-blinded, multi-center clinical trial, expecting to enroll 3,700 healthy subjects, 20 years of age and above.
  • "MVC isdelighted to receive the Phase 2 clinical trial INDapproval by Taiwan FDA forMVC-COV1901 vaccine" said Charles Chen, Chief Executive Officer at Medigen.
  • MVC-COV1901 is a subunit vaccine with recombinant S-2P antigen adjuvanted with CpG 1018 supplied by Dynavax plus aluminum hydroxide.

Vaxcyte Announces Publication of Preclinical Proof-of-Concept Data Supporting Potential of VAX-A1, a Novel Conjugate Vaccine Designed to Prevent Group A Strep Infections

Retrieved on: 
Wednesday, January 6, 2021
Medical specialties, Vaccination, Vaccine, Virology, Vaccines, Microbiology, Subunit vaccine, Clinical medicine, Streptococcal infections, Polysaccharide encapsulated bacteria, Group A streptococcal infection, Meningococcal vaccine

In the study, a novel protein and polysaccharide conjugate of the Group A Strep polysaccharide was constructed for inclusion in a universal subunit vaccine against infections by the pathogen.

Key Points: 
  • In the study, a novel protein and polysaccharide conjugate of the Group A Strep polysaccharide was constructed for inclusion in a universal subunit vaccine against infections by the pathogen.
  • Furthermore, by using conserved antigens, we believe that the vaccine could address the full range of pathogenic serotypes of Group A Strep.
  • Highlights of Findings from the Preclinical Study:
    The study examined the efficacy of a novel polysaccharide protein conjugate for a vaccine covering all serotypes of Group A Strep.
  • The vaccine is a combination of this novel conjugate with three additional highly conserved virulence factors, designed to cover all Group A Strep strains.